Dental software involves computer programs used for digital record-keeping, billing, insurance claims management, and clinical charting. They enhance the overall dental practice efficiency by streamlining operations and improving patient communication. Dental software helps dentists maintain electronic patient records, plan treatments, integrate digital x-rays and photos, handle billing and insurance claims, and schedule appointments - all in one place. The global dental software market size is estimated to be valued at US$ 2.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity to streamline dental practice operations and enhance overall efficiency is expected to drive the demand for dental software over the forecast period. Dental software helps automate tedious administrative tasks such as documentation, billing, and scheduling, freeing up dentists and staff to focus more on direct patient care. They offer enhanced productivity by integrating and centralizing important patient data, treatment plans, digital records, and communications in one platform. This streamlines workflows and minimizes errors, improving efficiency. Dental software improves collaboration within dental teams through role-based access and real-time updating of patient records. They offer opportunity to standardize treatment protocols and enhance compliance with best clinical practices. This is expected to boost their adoption among dental practices, fueling the growth of the global dental software market during the forecast period.
Porter’s Analysis
Threat of new entrants: The dental software market requires considerable investment to develop specialized software solutions for dentists and dental practices. Established players have strong brand recognition and a large customer base which creates barriers for new companies.
Bargaining power of buyers: Individual dental practices and clinics have limited bargaining power against large dental software providers due to fewer alternatives and switching costs involved. However, larger dental service organizations and hospital chains can negotiate on pricing.
Bargaining power of suppliers: A few large players dominate the supply of advanced dental software. However, availability of open source platforms provides alternatives to dental practices, balancing supplier leverage.
Threat of new substitutes: Alternatives such as cloud-based and mobile apps for dental patient engagement pose some disruption risk but cannot fully replace professional practice management software.
Competitive rivalry: The market is growing steadily but competition is intense among leading vendors to expand capabilities and global footprint.
SWOT Analysis
Strength: Dental software provides efficiency, data management, scheduling, billing and analytics benefits. Cloud platforms ensure accessibility from any device.
Weakness: Transitioning from paper to software involves initial costs. Technical issues and data security breaches can undermine customer confidence.
Opportunity: Emerging markets and rapid digitization offer scope for new customer acquisition. Analytics and AI-enabled personalization are growing areas.
Threats: Strict regulations around patient data privacy. Customers may favour low-cost open source alternatives.
Key Takeaways
The Global Dental Software Market Size is expected to witness high growth over the forecast period of 2023 to 2030. North America dominates the market currently due to advanced healthcare infrastructure and rising dental healthcare spending in the region. However, Asia Pacific is expected to show highest growth rate during the forecast period owing to growing medical tourism and increasing health awareness in emerging countries of China and India.
Key players operating in the Dental Software market include IBM Corporation, Microsoft Corporation, Cisco Systems, Inc., Oracle Corporation, Gemalto (Thales Group), RSA Security LLC (a subsidiary of Dell Technologies), Entrust Datacard Corporation, Auth0, ForgeRock, Ping Identity Corporation, OneSpan Inc., Okta, Inc., Nok Nok Labs, Inc., Signicat AS, Jumio Corporation. IBM and Microsoft have leading positions in dental patient management software globally due to their advanced cloud platforms. Smaller players are focused on developing innovative solutions for areas like dental imaging, treatment planning and analytics. The market is witnessing increasing adoption of cloud-based software and mobile apps for enhanced patient engagement.
For More Insights, Read: https://www.newswirestats.com/dental-software-market-demand-growth-and-regional-outlook-by-2030/
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
